Search PubMed⌕ Search

Biomedical subjects

A Galluccio

Publications and source records attributed to A Galluccio.

4 recordsLinked to original sources
PubMed2004

Critical thermodynamics of the two-dimensional +/-J Ising spin glass.

We compute the exact partition function of 2d Ising spin glasses with binary couplings. In these systems, the ground state is highly degenerate and is separated from the first excited state by a gap of size 4J. Nevertheless, we find that the low temperature specific heat density scales as exp(-2J/T), corresponding to an "effective" gap of size 2J; in addition, an associated crossover length scale grows as exp(J/T). We justify these scalings via the degeneracy of the low lying excitations and by the way low energy domain walls proliferate in this model.

Journal Article↗
PubMed2000

New algorithm for the Ising problem: partition function for finite lattice graphs.

We present a new efficient method to find the Ising problem partition function for finite lattice graphs embeddable on an arbitrary orientable surface, with integral coupling constants bounded in the absolute value by a polynomial of the size of the lattice graph. The algorithm has been implemented for toroidal lattices using modular arithmetic and the generalized nested dissection method. The implementation has substantially better performance than any other as far as we know.

Journal Article↗
PubMedDate not supplied

Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).

Etanercept is a soluble tumour necrosis factor receptor fusion protein which is approved for the treatment of plaque psoriasis at the dose of either 25mg twice weekly (BIW) or, for the initial 12 weeks, 50mg BIW. Alternative dosing regimens have not been evaluated in psoriasis. In this study, we compare the efficacy and tolerability of two etanercept dosing regimens--50mg BIW and 100mg once weekly (OW)--for 12 weeks in 108 patients with moderate-to-severe recalcitrant psoriasis. Efficacy measures included Psoriasis Area and Severity Index (PASI), severity of pruritus recorded on a visual analogue scale (VAS) and the influence on quality of life assessed by means of Dermatology Life Quality Index (DLQI). Both etanercept regimens caused a significant change in all the efficacy parameters after 4 weeks and 12 weeks, at a comparable rate. At week 12, a PASI improvement of at least 50% from baseline (PASI 50) was achieved by 74% of patients treated with 50mg BIW and 78% of patients treated with 100mg OW. A PASI 75 response was obtained in 54% and 50% of patients treated with 50mg BIW and 100mg OW, respectively. Treatment was well tolerated with similar type and frequency of adverse events between the two groups.

Adult↗